The purpose of this registry study is to investigate the effectiveness and safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of COVID-19 patients.
During the ongoing COVID-19 pandemic, millions of people have been infected with SARS- Cov-2
worldwide. In the absence of an approved vaccine or medical treatment, there is an emerging
need for treatment options, especially in critically ill patients. Multiple pharmacological
and non-pharmacological therapies are being investigated. In 2019, the Seraph® 100 Microbind®
Affinity Blood Filter (ExThera Medical Corporation, CA, USA) was approved for the removal of
pathogens in Europe. On April 17th the FDA granted Authorization for Emergency Use in
patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.
Device: Seraph 100
Seraph 100 therapy during a COVID-19 infection
Inclusion Criteria:
- COVID-19 infection
- Treatment with the Seraph® 100 Microbind® Affinity Blood Filter
- Voluntary consent to participate in Registry
Exclusion Criteria:
- none
Academic Teaching Hospital Brunswick
Brunswick, Lower Saxony, Germany
Hannover Medical School
Hannover, Germany
Julius J Schmidt, Dr
+495115326319
schmidt.julius@mh-hannover.de
Jan T Kielstein, Prof
+495315952380
kielstein@yahoo.com